Factors Associated with Low-Level Viraemia and Virological Failure: Results from the Austrian HIV Cohort Study.

Leierer, G, Grabmeier-Pfistershammer, K, Steuer, A, Geit, M, Sarcletti, M, Haas, B, Kanatschnig, M, Rappold, M, Zangerle, R, Ledergerber, B, Taylor, N. PLOS ONE. 2015, 10(11).

The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients.

Troppan, KT, Melchardt, T, Deutsch, A, Schlick, K, Stojakovic, T, Bullock, MD, Reitz, D, Beham-Schmid, C, Weiss, L, Neureiter, D, Wenzl, K, Greil, R, Neumeister, P, Egle, A, Pichler, M. Eur J Haematol. 2015, 95(6): 538-544.

The Role of CD44 in the Pathophysiology of Chronic Lymphocytic Leukemia.

Gutjahr, JC, Greil, R, Hartmann, TN. FRONT IMMUNOL. 2015, 6: 177.

The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial.

Fitzal, F, Filipits, M, Rudas, M, Greil, R, Dietze, O, Samonigg, H, Lax, S, Herz, W, Dubsky, P, Bartsch, R, Kronenwett, R, Gnant, M. Br J Cancer. 2015, 112(8): 1405-1410.

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up.

Ludwig, H, Greil, R, Masszi, T, Spicka, I, Shpilberg, O, Hajek, R, Dmoszynska, A, Paiva, B, Vidriales, MB, Esteves, G, Stoppa, AM, Robinson, D, Chaturvedi, S, Ataman, O, Enny, C, Feng, H, van de Velde, H, Viterbo, L. Br J Haematol. 2015, 171(3): 3-54.

Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial.

Jaeger, U, Trneny, M, Melzer, H, Praxmarer, M, Nawarawong, W, Ben Yehuda, D, Goldstein, D, Mihaljevic, B, Ilhan, O, Ballova, V, Hedenus, M, Hsiao, LT, Au, WY, Burgstaller, S, Weidinger, G, Keil, F, Dittrich, C, Skrabs, C, Klingler, A, Chott, A, Fridrik, MA, Greil, R. Haematologica. 2015, 100(7): 955-963.

Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction.

Ramos, F, ThГ©pot, S, Pleyer, L, Maurillo, L, Itzykson, R, Bargay, J, Stauder, R, Venditti, A, Seegers, V, MartГ­nez-Robles, V, Burgstaller, S, RГ©cher, C, DebГ©n, G, Gaidano, G, Gardin, C, Musto, P, Greil, R, SГЎnchez-Guijo, F, Fenaux, P. Leuk Res. 2015, 39(3): 296-306.

Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study.

Ludwig, H, Rauch, E, Kuehr, T, Adam, Z, Weissmann, A, Kasparu, H, Autzinger, EM, Heintel, D, Greil, R, Poenisch, W, MГјldГјr, E, Zojer, N. Haematologica. 2015, 100(3):385-391.

Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study.

Tiede, A, Klamroth, R, Scharf, RE, Trappe, RU, Holstein, K, Huth-Kühne, A, Gottstein, S, Geisen, U, Schenk, J, Scholz, U, Schilling, K, Neumeister, P, Miesbach, W, Manner, D, Greil, R, von Auer, C, Krause, M, Leimkühler, K, Kalus, U, Blumtritt, J, Werwitzke, S, Budde, E, Koch, A, Knöbl, P. Blood. 2015, 125(7): 1091-1097.

Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first disease progression (PD) in patients with metastatic colorectal cancer (mCRC) previously treated with BEV-based therapy: Outcomes according to KRAS status and first-line CT backbone in the ML18147 study.

Kubicka, S, Greil, R, Andre, T, Bennouna, J, Sastre, J, Van Cutsem, E, Von Moos, R, Osterlund, PJ, Hegde, P, Sersch, MA, Osborne, S, Hermann, F, Arnold, D J CLIN ONCOL. 2014, 32(3):